Showing 1 - 4 of 4 Items
Showing 1 - 4 of 4 Items
Sort By: Relevance
Journal Article
|Research
Effectiveness of bedaquiline use beyond six months in patients with multidrug-resistant tuberculosis
2023-06-01 • American Journal of Respiratory and Critical Care Medicine
2023-06-01 • American Journal of Respiratory and Critical Care Medicine
RATIONALE
Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform ...
Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform ...
Journal Article
|Research
2019-05-01 • Emerging Infectious Diseases
2019-05-01 • Emerging Infectious Diseases
Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 c...
Journal Article
|Research
2018-07-01 • International Journal of Tuberculosis and Lung Disease
2018-07-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND AND SETTING
Bedaquiline (BDQ) was initially only available through compassionate use programmes.
OBJECTIVE
To assess the effectiveness and safety of multidrug...
Bedaquiline (BDQ) was initially only available through compassionate use programmes.
OBJECTIVE
To assess the effectiveness and safety of multidrug...
Journal Article
|Research
2017-02-01 • International Journal of Tuberculosis and Lung Disease
2017-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of i...
For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of i...